Indications
Inflammation of the cornea
Besifloxacin ophthalmic suspension is indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following bacteria:
Corynebacterium pseudodiphtheriticum
Corynebacterium striatum
Haemophilus influenzae
Moraxella lacunata
Staphylococcus aureus
... Read more
Besifloxacin ophthalmic suspension is indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following bacteria:
Corynebacterium pseudodiphtheriticum
Corynebacterium striatum
Haemophilus influenzae
Moraxella lacunata
Staphylococcus aureus
Staphylococcus epidermidis
Staphylococcus hominis
Staphylococcus lugdunensis
Streptococcus mitis group
Streptococcus oralis
Streptococcus pneumoniae
Streptococcus salivarius
Efficacy for this organism was studied in fewer than 10 infections.
Dosage And Administration
Adults and children (1 year of age and older): Instill one drop in the affected eye(s) 3 times a day for 7 days.
Pediatric Use: The safety and effectiveness of Besifloxacin in infants below one year of age have not been established.
Side Effects
The most frequently reported ocular adverse event was conjunctival redness, reported in approximately 2% of patients. Other adverse events reported in patients receiving Besifloxacin occurring in approximately 1-2% of patients included: blurred vision, eye pain, eye irritation, eye pruritus and headache.
Precautions And Warnings
This drug is for topical ophthalmic use only and should not be injected subconjunctivally, nor should it be introduced directly into the anterior chamber of the eye. As with other anti-infectives, prolonged use may result in overgrowth of non-susceptible organisms, including fungi. If superinfection occurs, discontinue use and institute alternative therapy. To prevent contamination do not touch the tip of the dropper to eye, eyelid or any surface of the affected eye. Patients should not wear contact lenses during the course of therapy with this drug. Shake well before use.
Pregnancy And Lactation
Pregnancy Category C. No adequate and well-controlled studies are established in pregnant women. This drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Lactation: It is not known whether Besifloxacin is secreted in human milk or not. Caution should be exercised when Besifloxacin is administered to a nursing mother.